Verici Dx
Verici Dx is an AIM-listed kidney transplant diagnostics company that commercializes AI-driven RNA-signature blood tests (Tutivia, Clarava, Protega) covering pre- through post-transplant rejection and fibrosis risk, sold to U.S. transplant centers and globally licensed via Thermo Fisher.
- Company typePublic
- Founded2020
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Verici Dx firmographics
Firmographics- Name
- Verici Dx
- Legal name
- Verici Dx, Inc.
- Website
- https://vericidx.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Verici Dx is an AIM-listed kidney transplant diagnostics company that commercializes AI-driven RNA-signature blood tests (Tutivia, Clarava, Protega) covering pre- through post-transplant rejection and fibrosis risk, sold to U.S. transplant centers and globally licensed via Thermo Fisher.
- Ownership category
- akta.pro rank
Verici Dx industry classification
Industry- Product category
- Transplant Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)
- akta.pro secondary industries
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Verici Dx is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Verici Dx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Laboratory Developed Test (LDT) Sales: Verici Dx operates a CLIA-certified laboratory and offers its tests as LDTs, billing Medicare (CMS) and commercial insurance payers directly. Tutivia™ (CPT 0320U) and Clarava™ (CPT 0319U) are billed at $2,650 per test under the Medicare gapfill rate. Revenue is generated per test performed, representing a usage-based, transaction-based model. FY25 unaudited revenue was $3.8 million, a 250% increase year-over-year.
- Licensing and Royalty Revenue from Thermo Fisher Scientific: Verici Dx signed an exclusive global licensing agreement with Thermo Fisher Scientific in November 2023 to further develop an assay for pre-transplant prognostic testing (Clarava™/PTRA™), with Thermo Fisher commercially marketing the PTRA test. This generates licensing and royalty revenue for Verici Dx.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Medicare Rate - Tutivia™ / Clarava™ |
| Unit Pricing | Pay-as-you-go | Commercial Insurance - Tutivia™ |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Verici Dx product offering
Product offeringCore offering
Verici Dx operates a CLIA-certified clinical laboratory in Franklin, Tennessee that performs AI-assisted transcriptomic blood tests for kidney transplant patients. The company's core products — Tutivia™, Clarava™, and Protega™ — use next-generation RNA sequencing and a proprietary 17-gene mRNA signature to generate continuous risk scores (0–100) for pre-transplant rejection risk, post-transplant acute rejection, and long-term fibrosis/graft failure. Tests are billed under established CPT codes to Medicare and commercial payers.
Product overview
Verici Dx offers an integrated suite of three complementary diagnostic tests forming a kidney transplant platform: Tutivia™ (post-transplant acute rejection test, commercially launched January 2023), Clarava™ (pre-transplant prognosis test), and Protega™ (fibrosis/graft failure risk prediction). Together, these products enable end-to-end testing for kidney transplant patients from pre-transplant risk assessment through late-stage monitoring. The tests utilize RNA sequencing technology with proprietary AI algorithms to generate risk scores for clinicians.
Differentiator
Problem solved
Functional benefit
Brands
- Tutivia™: Post-transplant blood test for acute cellular rejection risk assessment in kidney transplant patients
- Clarava™
- Protega™
Products and services
- Tutivia™ A post-transplant blood-based prognostic test (CPT 0320U) for acute cellular rejection in kidney transplant recipients, using a 17-gene mRNA signature and proprietary AI/ML algorithm to generate continuous risk scores (0–100) and differentiate rejection from BK virus or ischemia-reperfusion injury. Sold to U.S. transplant centers and billed at $2,650 per test under Medicare.
- Clarava™ A pre-transplant prognosis test (CPT 0319U) that uses an RNA gene signature to define individual patient risk of early acute rejection during pre-transplant assessment, enabling personalized immunosuppression protocols. Billed at $2,650 per test under Medicare.
- Protega™ A liquid biopsy prognostic assay that analyzes multiple RNA biomarkers from peripheral blood post-kidney transplant to predict the risk of developing progressive fibrosis and long-term graft failure.
- CLIA-Certified Laboratory Testing Services Clinical laboratory testing services delivered from Verici Dx's CLIA-certified, CAP-accredited laboratory in Franklin, Tennessee, performing next-generation RNA sequencing and transcriptomic analysis for Verici Dx commercial tests including Tutivia™ and Clarava™.
- Bioinformatics / Sequencing Services Next-generation sequencing services including whole transcriptome, targeted RNASeq, exome analysis, RNA pipeline analysis, and multiomic signature discovery, supporting Verici Dx's diagnostic pipeline and data infrastructure.
Quantifiable outcome
- High-risk Tutivia™ result: hazard ratio of 5.74 for acute rejection over low-risk result (demonstrated in 151-patient multicenter validation study).
- +5 more outcomes
Companies that use Verici Dx
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Verici Dx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature3 records
Verici Dx partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- Thermo Fisher ScientificcoreVerici Dx signed an exclusive global licensing agreement with Thermo Fisher Scientific (November 2023) to further develop and commercialize an assay for pre-transplant prognostic testing (PTRA™/Clarava™) for risk of early kidney rejection. Thermo Fisher launched the pre-transplant risk assessment assay using technology licensed from Verici Dx, with clinical validation showing high-risk patients are seven times more likely to experience early acute rejection. This provides Verici Dx with global distribution reach and royalty revenue.
- American Kidney Fund (AKF)coreVerici Dx partners with the American Kidney Fund to support their programs in prevention, early detection, disease management, clinical research, innovation, and advocacy. CEO Sara Barrington has appeared in video discussions with AKF President LaVarne A. Burton on patient community and innovation in kidney care.
- American Society of Nephrology (ASN)coreVerici Dx partners with ASN to create a stronger focus on kidney health and advance the realization of a world without kidney diseases. ASN leads the fight against kidney disease through education, journals, self-assessment, and distant learning opportunities. Verici Dx presents data at ASN Kidney Week and collaborates on educational initiatives.
- American Society of Transplantation (AST)coreVerici Dx partners with AST to support their dedication to advancing the field of transplantation and improving patient care. AST is the largest transplant organization in North America with over 4,000 professionals. The partnership includes educational content, research collaboration, and clinical community engagement.
- American Society of Transplant Surgeons (ASTS)coreVerici Dx partners with ASTS to support transplant surgeons, physicians, scientists, and allied health professionals striving to advance the art and science of transplant surgery. ASTS represents over 1,900 professionals globally. CEO Sara Barrington has engaged in video discussions with ASTS leadership on priorities and collaboration.
- KDIGO (Kidney Disease: Improving Global Outcomes)coreVerici Dx supports KDIGO's global promotion of awareness, dissemination, adoption, and clinical integration of KDIGO Clinical Practice Guidelines. KDIGO develops evidence-based clinical practice guidelines for kidney disease and convenes Controversies Conferences and implementation activities.
- National Kidney Foundation (NKF)coreVerici Dx supports NKF's passion to improve, sustain, and extend the lives of those living with kidney disease. NKF is a leading organization in kidney disease awareness, prevention, and treatment, offering CME/CE programs and conducting research to advance kidney disease treatment and patient outcomes.
- Amazon Web Services (AWS) / IlluminacoreVerici Dx uses AWS and Illumina Connected Analytics for next-generation sequencing data processing and cloud-based analysis. The AWS Case Study documents how Verici Dx leverages cloud infrastructure for parallel processing to accelerate personalized diagnostic testing workflows.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Verici Dx competitors and assessment
Company assessmentDirect peers
- Natera: Natera's Prospera™ is a dd-cfDNA kidney transplant rejection test, directly competing with Tutivia™ for the same transplant nephrology prescribing decisions and Medicare reimbursement. Both companies pursue molecular transplant surveillance via blood-based assays.
- Immucor: Immucor specializes in transfusion and transplantation diagnostics including HLA typing and antibody detection reagents used by U.S. transplant centers. It is a direct peer in serving the transplant immunology workflow upstream of Verici's rejection diagnostics.
- CareDx: CareDx is the leading transplant diagnostics company with AlloSure (dd-cfDNA) for kidney transplant rejection, the most direct competitor to Tutivia™ in post-transplant rejection assessment. It shares the same transplant center customer base and reimbursement-driven LDT business model.
- Eurofins Viracor: Eurofins Viracor is a specialty transplant immunology laboratory offering HLA testing, donor-specific antibody, and infectious-disease panels to U.S. transplant centers. It competes for the same clinical workflow decisions and serves as an alternative diagnostic partner for transplant programs.
Broad incumbents
- Labcorp: Labcorp is a national clinical laboratory serving transplant programs with HLA typing, infectious disease, and routine chemistry panels. As a broad incumbent, it competes for transplant-center reference work where Verici Dx is currently sub-scale.
- Quest Diagnostics: Quest Diagnostics is one of the largest U.S. clinical reference labs offering transplant-relevant infectious disease, HLA, and some rejection biomarker testing. It competes indirectly as a broad incumbent that captures routine transplant testing volume and could expand into molecular rejection diagnostics.
Others
- Bio-Rad Laboratories: Bio-Rad supplies HLA typing and transplant-related blood-bank reagents widely used in transplant immunology workflows. It is an enabling peer (reagent/instrument vendor) rather than a direct competitor, providing adjacent technology to transplant centers.
- Thermo Fisher Scientific (One Lambda): Thermo Fisher is simultaneously Verici Dx's exclusive global PTRA licensee and a transplant-diagnostics incumbent through its One Lambda HLA product line. It represents both a strategic partner and a competitor controlling parts of the transplant testing workflow.
Emerging players
- Renalytix: Renalytix plc (KidneyIntelX) is a London-listed diagnostics peer with AI/ML biomarker tests for kidney disease risk assessment, sharing Verici Dx's transplant-nephrology and AI-driven kidney diagnostics focus. Both are AIM-listed small-cap kidney diagnostics companies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Verici Dx social profiles
Digital presenceVerici Dx compliance and trust
Trust signalCompliance4 records
Verici Dx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Verici Dx leadership team
Management profileNumber of profiles
Profiles6 records
Verici Dx funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Verici Dx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Verici Dx
What does Verici Dx do?
Verici Dx operates a CLIA-certified clinical laboratory in Franklin, Tennessee that performs AI-assisted transcriptomic blood tests for kidney transplant patients. The company's core products — Tutivia™, Clarava™, and Protega™ — use next-generation RNA sequencing and a proprietary 17-gene mRNA signature to generate continuous risk scores (0–100) for pre-transplant rejection risk, post-transplant acute rejection, and long-term fibrosis/graft failure. Tests are billed under established CPT codes to Medicare and commercial payers.
Is Verici Dx a public or private company?
Verici Dx is a public company. It is classified as public and is currently operating.
When was Verici Dx founded?
Verici Dx was founded in 2020. It employs 11 to 50 people.
Where is Verici Dx based?
Verici Dx is headquartered in New York, United States, in the North America region.
How does Verici Dx make money?
Two revenue lines are on record. Laboratory Developed Test (LDT) Sales are the primary driver. The others are licensing and Royalty Revenue from Thermo Fisher Scientific.
Who are Verici Dx's main competitors?
Direct peers on record are Natera, Immucor, CareDx and Eurofins Viracor. Broad incumbents are Labcorp and Quest Diagnostics. Others are Bio-Rad Laboratories and Thermo Fisher Scientific (One Lambda). Renalytix is listed as an emerging player.
Does Verici Dx have an API?
No public API is recorded for Verici Dx.
What industry is Verici Dx in?
Verici Dx's product category is Transplant Diagnostics. Its primary akta.pro industry code is HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays, with a secondary code of HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing. Its NAICS code is 621511 and its SIC code is 8071.